Biokin’s world-first bispecific ADC hits milestones, speeding commercialization
Iza-bren was approved for recurrent or metastatic esophageal squamous cell carcinoma, after receiving earlier approval to treat nasopharyngeal carcinoma Key Takeaways: New approvals for Biokin’s Iza-bren highlight the rise of…
BRIEF: Sichuan Biokin launches Hong Kong IPO, eyes Stock Connect program entry
Biopharmaceutical company Sichuan Biokin Pharmaceutical (2615.HK; 688506.SH) launched its Hong Kong IPO on Friday, aiming to raise up to HK$3.36 billion ($432 million) by selling 8.63 million shares for between…
Recent Articles
RELATED ARTICLES
-
Jacobio Pharma poised to turn a profit from precision cancer drugs
-
InnoCare hits profit milestone, enters new phase with global expansion, strong pipeline
9969.HK688428.SHG
- A healthy return: drug spin-off nets Keymed up to $320 million
- Insilico revenue soars above $100 million on AI drug partnerships
- Mega licensing deal lifts 3SBio profits but core sales slip
-
Then there were two: BeOne moves beyond single-blockbuster dependence
6160.HK688235.SHGONC.US
-
TransThera completes late-stage trial enrollment for Tinengotinib cancer drug
2617.HK
